

Simon Å¹/₂akelj

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4773838/publications.pdf>

Version: 2024-02-01

26
papers

646
citations

687363

13
h-index

580821

25
g-index

26
all docs

26
docs citations

26
times ranked

1064
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Indoles and 1-(3-(benzyloxy)benzyl)piperazines: Reversible and selective monoamine oxidase B inhibitors identified by screening an in-house compound library. <i>Bioorganic Chemistry</i> , 2022, 119, 105581. | 4.1 | 2 |
| 2 | Applicability of RPMI 2650 and Calu-3 Cell Models for Evaluation of Nasal Formulations. <i>Pharmaceutics</i> , 2022, 14, 369. | 4.5 | 11 |
| 3 | A Fine-Tuned Lipophilicity/Hydrophilicity Ratio Governs Antibacterial Potency and Selectivity of Bifurcated Halogen Bond-Forming NBTIs. <i>Antibiotics</i> , 2021, 10, 862. | 3.7 | 9 |
| 4 | Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor. <i>Scientific Reports</i> , 2021, 11, 18098. | 3.3 | 12 |
| 5 | Multitarget 2- α -hydroxychalcones as potential drugs for the treatment of neurodegenerative disorders and their comorbidities. <i>Neuropharmacology</i> , 2021, 201, 108837. | 4.1 | 6 |
| 6 | Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 1361-1387. | 6.4 | 33 |
| 7 | <i>Echinacea angustifolia</i> DC. Lipophilic Extract Patch for Skin Application: Preparation, In Vitro and In Vivo Studies. <i>Pharmaceutics</i> , 2020, 12, 1096. | 4.5 | 3 |
| 8 | Suitability and functional characterization of two Calu-3 cell models for prediction of drug permeability across the airway epithelial barrier. <i>International Journal of Pharmaceutics</i> , 2020, 585, 119484. | 5.2 | 22 |
| 9 | N-alkylpiperidine carbamates as potential anti-Alzheimer's agents. <i>European Journal of Medicinal Chemistry</i> , 2020, 197, 112282. | 5.5 | 33 |
| 10 | Biopharmaceutical classification of desloratadine – not all drugs are classified the easy way. <i>Acta Pharmaceutica</i> , 2020, 70, 131-144. | 2.0 | 6 |
| 11 | Suitability of RPMI 2650 cell models for nasal drug permeability prediction. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 145, 85-95. | 4.3 | 25 |
| 12 | A review of methods for solubility determination in biopharmaceutical drug characterization. <i>Drug Development and Industrial Pharmacy</i> , 2019, 45, 1717-1724. | 2.0 | 50 |
| 13 | The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 119-139. | 6.4 | 112 |
| 14 | Mechanical properties and drug permeability of the PA6 membranes prepared by immersion precipitation from PA6 – formic acid – water system. <i>Journal of Membrane Science</i> , 2018, 562, 67-75. | 8.2 | 3 |
| 15 | Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 598-617. | 5.5 | 72 |
| 16 | Identification and characterization of the novel reversible and selective cathepsin X inhibitors. <i>Scientific Reports</i> , 2017, 7, 11459. | 3.3 | 15 |
| 17 | Development of an in-vivo active reversible butyrylcholinesterase inhibitor. <i>Scientific Reports</i> , 2016, 6, 39495. | 3.3 | 105 |
| 18 | Thematic issue on drug delivery for specific populations. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 75, 1. | 4.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 2194-2207. | 3.0 | 20 |
| 20 | Absorption and elimination of imatinib through the rat intestine in vitro. <i>International Journal of Pharmaceutics</i> , 2014, 460, 144-149. | 5.2 | 3 |
| 21 | Do the Recommended Standards for In Vitro Biopharmaceutic Classification of Drug Permeability Meet the "Passive Transport" Criterion for Biowaivers?. <i>Current Drug Metabolism</i> , 2013, 14, 21-27. | 1.2 | 7 |
| 22 | Do the recommended standards for in vitro biopharmaceutic classification of drug permeability meet the "passive transport" criterion for biowaivers?. <i>Current Drug Metabolism</i> , 2013, 14, 21-7. | 1.2 | 3 |
| 23 | In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. <i>European Journal of Nutrition</i> , 2010, 49, 373-384. | 3.9 | 24 |
| 24 | Ciprofloxacin permeability and its active secretion through rat small intestine in vitro. <i>International Journal of Pharmaceutics</i> , 2006, 313, 175-180. | 5.2 | 45 |
| 25 | The Effect of Clodronate on the Integrity and Viability of Rat Small Intestine in Vitro-A Comparison with EDTA. <i>Biological and Pharmaceutical Bulletin</i> , 2005, 28, 1249-1253. | 1.4 | 2 |
| 26 | The influence of buffer composition on tissue integrity during permeability experiments "in vitro". <i>International Journal of Pharmaceutics</i> , 2004, 272, 173-180. | 5.2 | 23 |